Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements executed by the GlaxoSmithKline Employee Trust ("GSK Trust") on behalf of employee plan participants:
- April 19, 2006: Transfer of 16,046 Ordinary Shares under the SmithKline Beecham Employee Share Option Plan 1991.
- April 20, 2006: Transfer of 8,400 Ordinary Shares under the SmithKline Beecham Employee Share Option Plan 1991.
- April 20, 2006: Sale of 3,420 Ordinary Shares under the GlaxoSmithKline Performance Share Plan at GBP 14.99 per share.
- April 20, 2006: Transfer of 7,179 Ordinary Shares to participants in the GlaxoSmithKline Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the GSK Trust as potential beneficiaries alongside other employees.
Investor Verification Points
- Verify the total volume of shares transferred or sold by the GSK Trust during the reporting period.
- Confirm the transaction price of GBP 14.99 per share for the Performance Share Plan sale.
- Review the specific employee plans (SmithKline Beecham 1991 and GlaxoSmithKline Performance Share Plan) governing these transactions.